Debt-to-equity in % of Atea Pharmaceuticals, Inc. from Q2 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Atea Pharmaceuticals, Inc. quarterly Debt-to-equity history and change rate from Q2 2021 to Q3 2025.
  • Atea Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 7%, a 8.1% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Atea Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 7% -1% -8.1% 30 Sep 2025
Q2 2025 7% 0% -2.7% 30 Jun 2025
Q1 2025 7% +1% +9.9% 31 Mar 2025
Q4 2024 8% +3% +61% 31 Dec 2024
Q3 2024 8% +4% +97% 30 Sep 2024
Q2 2024 7% +3% +90% 30 Jun 2024
Q1 2024 6% +2% +54% 31 Mar 2024
Q4 2023 5% 0% +2% 31 Dec 2023
Q3 2023 4% -2% -32% 30 Sep 2023
Q2 2023 4% -11% -75% 30 Jun 2023
Q1 2023 4% -21% -84% 31 Mar 2023
Q4 2022 5% -30% -87% 31 Dec 2022
Q3 2022 6% -42% -88% 30 Sep 2022
Q2 2022 15% -37% -71% 30 Jun 2022
Q1 2022 25% 31 Mar 2022
Q4 2021 34% 31 Dec 2021
Q3 2021 48% 30 Sep 2021
Q2 2021 52% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.